Dashboard
Manage Tickers

KURA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

kura-scores-a-big-win-as-fda-approves-its-new-leukemia-pill
Kura Scores A Big Win As FDA Approves Its ...
11/14/2025 17:43:58

Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price ...

ubs-maintains-buy-on-kura-oncology-raises-price-target-to-16
UBS Maintains Buy on Kura Oncology, Raises...
11/14/2025 17:13:45

UBS analyst David Dai maintains Kura Oncology (NASDAQ:KURA) with a Buy and raises the price target from $14 to $16.

wedbush-maintains-outperform-on-kura-oncology-raises-price-target-to-38
Wedbush Maintains Outperform on Kura Oncol...
11/14/2025 15:15:58

Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raises the price target from $36...

kura-oncology-exec-says-already-in-dialog-with-fda-about-potential-steps-post-approval-that-could-help-refine-labeling
Kura Oncology Exec Says: Already In Dialog...
11/13/2025 18:07:08

- Conf Call

trading-halt-halt-status-updated-at-112500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 11:25...
11/13/2025 16:25:04

fda-approves-ziftomenib-for-relapsed-or-refractory-acute-myeloid-leukemia-with-a-npm1-mutation
FDA Approves Ziftomenib For Relapsed Or Re...
11/13/2025 15:15:44

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leu...

trading-halt-halted-at-95953-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 9:59:53 a.m. ET - ...
11/13/2025 14:59:57

kura-oncology-q3-eps-085-misses-084-estimate-sales-20750m-miss-41259m-estimate
Kura Oncology Q3 EPS $(0.85) Misses $(0.84...
11/04/2025 11:34:40

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.8...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

kura-oncology-gets-30m-milestone-payment-under-partnership-agreement-with-kyowa-kirin-in-dosing-first-participant-in-second-komet-017-phase-3-registration-trials-of-ziftomenib
Kura Oncology Gets $30M Milestone Payment ...
11/03/2025 21:11:04

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision ...

kura-oncology-to-feature-results-from-komet-007-combination-trial-of-ziftomenib-oral-investigational-menin-inhibitor-at-ash-2025
Kura Oncology To Feature Results From KOME...
11/03/2025 14:25:08

– Data to be featured in two oral presentations on December 8, 2025 –– Broad development program assesses ziftomenib across div...

kura-oncology-scores-30-million-boost-as-new-leukemia-drug-enters-major-trial
Kura Oncology Scores $30 Million Boost As ...
10/24/2025 16:17:11

Kura Oncology rises after $30M milestone from Kyowa Kirin; Phase 3 ziftomenib dosing and FTI data at ESMO bolster pipeline.

kura-oncology-receives-30m-development-milestone-payment-under-its-collaboration-with-kyowa-kirin-from-dosing-first-patient-in-komet-017-phase-3-trial
Kura Oncology Receives $30M Development Mi...
10/24/2025 11:03:24

jmp-securities-reiterates-market-outperform-on-kura-oncology-maintains-24-price-target
JMP Securities Reiterates Market Outperfor...
10/20/2025 13:37:22

JMP Securities analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 pr...

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
10/20/2025 11:49:25

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $40 price t...

reported-saturday-kura-oncology-presents-new-esmo-2025-data-showing-darlifarnib-plus-cabozantinib-delivers-50-orr-in-rcc-fti-programs-demonstrate-robust-activity-and-manageable-safety-profile
Reported Saturday, Kura Oncology Presents ...
10/20/2025 08:19:09

FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapiesEarly clinical and preclin...

kura-oncology-and-kyowa-kirin-announce-dosing-of-first-patient-in-cohort-of-komet-007-clinical-trial
Kura Oncology And Kyowa Kirin Announce Dos...
10/01/2025 11:11:48

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhib...

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
09/30/2025 10:54:42

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $40 price t...

kura-oncology-and-kyowa-kirin-dose-first-patient-in-phase-3-komet-017-trial-of-ziftomenib-for-frontline-acute-myeloid-leukemia
Kura Oncology And Kyowa Kirin Dose First P...
09/29/2025 20:01:50

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION